COMBI Stock Overview
Engages in the development of gene therapy for severe life-altering diseases in Sweden.
Snowflake Score | |
---|---|
Valuation | 2/6 |
Future Growth | 0/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
CombiGene AB (publ) Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | SEK 2.76 |
52 Week High | SEK 7.40 |
52 Week Low | SEK 2.00 |
Beta | 1.38 |
11 Month Change | -10.97% |
3 Month Change | -25.41% |
1 Year Change | -56.54% |
33 Year Change | -66.75% |
5 Year Change | -90.28% |
Change since IPO | -98.46% |
Recent News & Updates
Shareholder Returns
COMBI | SE Biotechs | SE Market | |
---|---|---|---|
7D | -5.5% | -5.9% | -6.7% |
1Y | -56.5% | 13.3% | 9.9% |
Return vs Industry: COMBI underperformed the Swedish Biotechs industry which returned 18% over the past year.
Return vs Market: COMBI underperformed the Swedish Market which returned 12.6% over the past year.
Price Volatility
COMBI volatility | |
---|---|
COMBI Average Weekly Movement | 8.1% |
Biotechs Industry Average Movement | 8.6% |
Market Average Movement | 5.9% |
10% most volatile stocks in SE Market | 12.2% |
10% least volatile stocks in SE Market | 3.5% |
Stable Share Price: COMBI's share price has been volatile over the past 3 months.
Volatility Over Time: COMBI's weekly volatility (8%) has been stable over the past year.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1990 | 10 | Peter Ekolind | www.combigene.com |
CombiGene AB (publ) engages in the development of gene therapy for severe life-altering diseases in Sweden. The company is developing two candidates for severe chronic pain conditions, which are in preclinical studies include COZY01, a peptide treatment; and COZY02, a gene therapy treatment. It is also developing CG01, an adeno-associated virus-based gene therapy targeting epileptic seizures.
CombiGene AB (publ) Fundamentals Summary
COMBI fundamental statistics | |
---|---|
Market cap | SEK 54.65m |
Earnings (TTM) | -SEK 35.24m |
Revenue (TTM) | SEK 6.21m |
8.8x
P/S Ratio-1.6x
P/E RatioIs COMBI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
COMBI income statement (TTM) | |
---|---|
Revenue | SEK 6.21m |
Cost of Revenue | SEK 26.23m |
Gross Profit | -SEK 20.02m |
Other Expenses | SEK 15.22m |
Earnings | -SEK 35.24m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
Aug 23, 2024
Earnings per share (EPS) | -1.78 |
Gross Margin | -322.56% |
Net Profit Margin | -567.69% |
Debt/Equity Ratio | 0% |
How did COMBI perform over the long term?
See historical performance and comparison